Diana Borenshtein is a distinguished scientist and executive with over 20 years of experience in the biotechnology and pharmaceutical sectors. Holding a Ph.D. in Molecular and Systems Toxicology from MIT, Diana has recently been appointed as the Vice President of Health and Life Sciences at Kanda Software. Prior to this role, she served as a Clinical Applications Manager and Cell and Gene Therapy Specialist at Miltenyi Biotec, where she contributed significantly to advancements in gene therapy and drug discovery.Diana is recognized as one of the Top 100 Women Scientists and is actively involved in research and development projects that aim to revolutionize patient care through innovative therapies. Her work primarily focuses on the clinical applications of cell and gene therapies, a field where she has published numerous articles and delivered keynote speeches at international conferences.Based in the United States, Diana maintains a strong online presence on social media platforms like Facebook and LinkedIn, engaging with a global audience to share insights and discuss the latest trends in health sciences. She is also an alumna of the prestigious MIT Sloan Artificial Intelligence in Pharma and Biotech online program, further highlighting her commitment to integrating AI technologies in biomedicine. Diana's leadership and expertise continue to influence the evolving landscape of healthcare technology and research.